fda remove semaglutide from shortage list Novo's Wegovy and Ozempic removed US list, compounders on notice Semaglutide taken off FDA's drug
Description
Research in Obesity journal documented that patients who stopped semaglutide without lifestyle intervention regained approximately two-thirds of their weight loss by month 12

Initiation rates for AOM GLP-1 RA increased substantially in March 2024, relative to December 2023 (+41.41%)
GLP-1s open a door, but lasting health comes from how we walk through it guided by sleep, calm, purpose, and connection. Dive into our GLP-1 resource center for stories on weight loss, medications, side effects, and more
SPC, summary of product characteristics
Telehealth excels in supporting weight loss journeys, but diabetes care involves regular examinations and tests that cannot be purely digital
